Editas Medicine Inc (NASDAQ: EDIT) kicked off on Tuesday, down -1.52% from the previous trading day, before settling in for the closing price of $4.61. Over the past 52 weeks, EDIT has traded in a range of $4.57-$11.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 101.57%. While this was happening, its average annual earnings per share was recorded -32.02%. With a float of $81.53 million, this company’s outstanding shares have now reached $81.77 million.
Let’s determine the extent of company efficiency that accounts for 265 employees.
Editas Medicine Inc (EDIT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.86%, while institutional ownership is 83.75%. The most recent insider transaction that took place on Jun 04 ’24, was worth 66,997. In this transaction CEO of this company sold 12,191 shares at a rate of $5.50, taking the stock ownership to the 315,279 shares. Before that another transaction happened on Jun 04 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 511 for $5.50, making the entire transaction worth $2,808. This insider now owns 141,032 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -32.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Take a look at Editas Medicine Inc’s (EDIT) current performance indicators. Last quarter, stock had a quick ratio of 4.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.10, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.61 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 2.32 million, which is a jump from its year-to-date volume of 1.98 million. As of the previous 9 days, the stock’s Stochastic %D was 8.15%. Additionally, its Average True Range was 0.32.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 1.26%, which indicates a significant decrease from 5.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.84% in the past 14 days, which was lower than the 76.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.37, while its 200-day Moving Average is $7.54. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $4.63. Second resistance stands at $4.72. The third major resistance level sits at $4.81. If the price goes on to break the first support level at $4.45, it is likely to go to the next support level at $4.36. Should the price break the second support level, the third support level stands at $4.27.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
The company with the Market Capitalisation of 373.37 million has total of 82,238K Shares Outstanding. Its annual sales at the moment are 78,120 K in contrast with the sum of -153,220 K annual income. Company’s last quarter sales were recorded 1,140 K and last quarter income was -61,950 K.
